Beyfortus (nirsevimab-alip) 50 mg and 100 mg Injection for Your Practice

Order Beyfortus Packaging Image

Start Planning for the 2024/2025 Season Today

Important Update Regarding Beyfortus Supply

There has been an unprecedented demand for Beyfortus. Despite an aggressive supply plan built with the goal of outperforming past pediatric immunization launches, the actual market demand has been much higher across both the 50 mg and 100 mg presentations.

At the present time, demand has now consumed the supply currently available for this season for both the 50 mg and 100 mg.

The Centers for Disease Control and Prevention (CDC) has issued a Health Alert Network (HAN) Health Advisory to provide options for clinicians to protect infants from RSV in the context of limited Beyfortus supply. Click here to learn more about the CDC Health Alert.

We understand the significant impact the supply shortage will have on parents and providers and apologize for this unfortunate circumstance. We are working earnestly to help make available future supplies of Beyfortus. Thank you for your patience.

Please contact your Sanofi representative to discuss any additional questions or sign up for updates.

For additional information, read the Sanofi press release.
For more information regarding Beyfortus, call 1-855-BEYFORTUS (1-855-239-3678)

How Beyfortus is supplied¹

Beyfortus injection is a sterile, preservative-free, clear to opalescent, colorless to yellow solution supplied as follows:

• Five 50 mg/0.5 mL single-dose pre-filled syringes in a carton: NDC 49281-575-15
• Five 100 mg/mL single-dose pre-filled syringes in a carton: NDC 49281-574-15

Each Beyfortus pre-filled syringe is for one-time use only.

Only 5-pack cartons will be available in the US at this time.
Order Beyfortus Packaging Image
Additional ordering details:

• Extended payment terms: 2% Prompt Pay 150, net 151 days
• All offers valid on orders received through March 31, 2024
• Product is fully returnable upon expiration


Beyfortus is indicated for the prevention of respiratory syncytial virus (RSV) lower respiratory tract disease in:

  • Neonates and infants born during or entering their first RSV season.
  • Children up to 24 months of age who remain vulnerable to severe RSV disease through their second RSV season.

Important safety information


Beyfortus is contraindicated in infants and children with a history of serious hypersensitivity reactions, including anaphylaxis, to nirsevimab-alip or to any of the excipients.

Warnings and Precautions

  • Hypersensitivity Including Anaphylaxis: Serious hypersensitivity reactions, including anaphylaxis, have been observed with other human IgG1 monoclonal antibodies. If signs and symptoms of a clinically significant hypersensitivity reaction or anaphylaxis occur, initiate appropriate medications and/or supportive therapy.
  • Use in Individuals with Clinically Significant Bleeding Disorders: As with other IM injections, Beyfortus should be given with caution to infants and children with thrombocytopenia, any coagulation disorder or to individuals on anticoagulation therapy.

Most common adverse reactions with Beyfortus were rash (0.9%) and injection site reactions (0.3%).

Click here to learn more about Sanofi’s commitment to fighting counterfeit drugs.